Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP980313.RAbkA9ieX1kgXI_HxZOrz_fUnrG28YPvvghMqz-ypMHFU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP980313.RAbkA9ieX1kgXI_HxZOrz_fUnrG28YPvvghMqz-ypMHFU130_assertion type Assertion NP980313.RAbkA9ieX1kgXI_HxZOrz_fUnrG28YPvvghMqz-ypMHFU130_head.
- NP980313.RAbkA9ieX1kgXI_HxZOrz_fUnrG28YPvvghMqz-ypMHFU130_assertion description "[This study evaluated the preclinical activity of selumetinib (AZD6244, ARRY-142866), an inhibitor of the mitogen-activated protein kinase kinase (MAPKK or MEK1/2) in 6 nasopharyngeal cancer (NPC) cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP980313.RAbkA9ieX1kgXI_HxZOrz_fUnrG28YPvvghMqz-ypMHFU130_provenance.
- NP980313.RAbkA9ieX1kgXI_HxZOrz_fUnrG28YPvvghMqz-ypMHFU130_assertion evidence source_evidence_literature NP980313.RAbkA9ieX1kgXI_HxZOrz_fUnrG28YPvvghMqz-ypMHFU130_provenance.
- NP980313.RAbkA9ieX1kgXI_HxZOrz_fUnrG28YPvvghMqz-ypMHFU130_assertion SIO_000772 22565394 NP980313.RAbkA9ieX1kgXI_HxZOrz_fUnrG28YPvvghMqz-ypMHFU130_provenance.
- NP980313.RAbkA9ieX1kgXI_HxZOrz_fUnrG28YPvvghMqz-ypMHFU130_assertion wasDerivedFrom befree-2016 NP980313.RAbkA9ieX1kgXI_HxZOrz_fUnrG28YPvvghMqz-ypMHFU130_provenance.
- NP980313.RAbkA9ieX1kgXI_HxZOrz_fUnrG28YPvvghMqz-ypMHFU130_assertion wasGeneratedBy ECO_0000203 NP980313.RAbkA9ieX1kgXI_HxZOrz_fUnrG28YPvvghMqz-ypMHFU130_provenance.